During the corresponding time, Scynexis Inc saw a revenue deteriorated by -82.77 % year on year, While revenue at the Scynexis Inc 's corporate clients
Scynexis Inc's Comment on Sales, Marketing and Customers
The company’s potential customers include entities involved in the U.S. pharmaceutical market, subject to legislative and regulatory actions concerning drug pricing. Key regulatory and legislative measures include Congressional inquiries, Presidential executive orders, and federal and state legislation aimed at increasing transparency in product pricing, reviewing pricing and manufacturer patient programs, and reforming government reimbursement methodologies. Notable programs include the Medicare Drug Price Negotiation Program, which targets high-expenditure, single-source drugs under Medicare Part B and Part D, with price negotiations commencing in fiscal year 2023 and continuing annually. The Bayh-Dole Act’s march-in rights initiative is also relevant for controlling prescription drug prices. At the state level, legislation such as Florida’s Section 804 Importation Program (SIP) permits the importation of certain drugs from Canada for state healthcare programs, with similar proposals under consideration in other states. Federal agencies involved in these regulatory actions include the Department of Health and Human Services (HHS), the Food and Drug Administration (FDA), and the Centers for Medicare & Medicaid Services (CMS). The Office of Management and Budget (OMB) also plays a role in overseeing regulatory policies. Current policies under the Trump administration aimed at reducing regulations and expenditures across government agencies may influence the business environment.
In a significant stride towards combating the challenge posed by invasive fungal infections, SCYNEXIS, Inc. (NASDAQ: SCYX) has initiated dosing in its Phase 1 clinical trial of SCY-247, a second-generation triterpenoid antifungal agent. Announced on December 18, 2024, this milestone is not only a testament to SCYNEXIS s commitment to developing innovative treatments but also highlights the pressing need for effective therapeutics in a field plagued by resistance and limited options. The Clinical Trial and Drug Profile SCY-247 is being developed as a novel therapeutic option for patients suffering from severe invasive fungal infections an area where traditional antifungal treatments often fall short, particu...
Scynexis Inc’s Comment on Sales, Marketing and Customers
The company’s potential customers include entities involved in the U.S. pharmaceutical market, subject to legislative and regulatory actions concerning drug pricing. Key regulatory and legislative measures include Congressional inquiries, Presidential executive orders, and federal and state legislation aimed at increasing transparency in product pricing, reviewing pricing and manufacturer patient programs, and reforming government reimbursement methodologies. Notable programs include the Medicare Drug Price Negotiation Program, which targets high-expenditure, single-source drugs under Medicare Part B and Part D, with price negotiations commencing in fiscal year 2023 and continuing annually. The Bayh-Dole Act’s march-in rights initiative is also relevant for controlling prescription drug prices. At the state level, legislation such as Florida’s Section 804 Importation Program (SIP) permits the importation of certain drugs from Canada for state healthcare programs, with similar proposals under consideration in other states. Federal agencies involved in these regulatory actions include the Department of Health and Human Services (HHS), the Food and Drug Administration (FDA), and the Centers for Medicare & Medicaid Services (CMS). The Office of Management and Budget (OMB) also plays a role in overseeing regulatory policies. Current policies under the Trump administration aimed at reducing regulations and expenditures across government agencies may influence the business environment.
Sources:
Scynexis Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Scynexis Inc’s corporate clients.
For your research, we’ve provided 9 tables on Scynexis Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
100 %